source
- Roche signs up to $813M deal with Zymeworks for preclinical trispecific T cell engagerRoche announced a partnership with Zymeworks that includes an upfront payment of $55 million for worldwide rights to a trispecific T cell engager currently in preclinical development. The agreemen…
- Bristol Myers reports patient death in autoimmune CAR-T trial and explains summer pauseBristol Myers Squibb disclosed that a participant in its autoimmune CAR-T cell therapy study has died. The company said the death occurred during the trial and is under investigation, with details…